OB Pharmaceuticals has developed a new class of medications We are dedicated to improving quality of life for individuals with epilepsy It’s time to change the paradigm of care

Working Together to Change the World

Owen Barry Pharmaceuticals began operations in 2014 to undertake the research and development of a new class of molecules that show promise for the treatment of epilepsy and brain injury related seizures.

Epilepsy is a chronic neurological spectrum disorder affecting nearly 65 million people worldwide and is characterized by recurrent and often debilitating seizures. More than 30% are or become refractory to current medications.

A seizure is abnormal (excessive) electrical activity of the brain that results in some sort of impairment such as the loss of consciousness and / or involuntary muscle movements.

Latest from the Blog

New Patents Awarded


LONDON, ONTARIO June 12, 2020 — OB Pharmaceuticals has been granted patent US 10,618,870 from the U.S. Patent and... Read More